The Numb/Parkin-guided mitochondrial adaptation serves as a key metabolic switch for cancer cell plasticity and emerges as a promising target for cancer therapy, emphasizing the link between mitochondrial function and tumor cell resistance [52]. This evidence concerns the gene PRKN and cancer.